Review maps NSCLC-to-SCLC transformation amid expanding lung cancer treatments

A 2026 review in Medical Oncology provides a broad synthesis of histologic and molecular transformation from non–small cell lung cancer (NSCLC) to small cell lung cancer (SCLC). The article is a review of published evidence rather than a new clinical trial or prospective patient study. Its scope includes the classification of NSCLC subtypes, clinical manifestations of SCLC transformation, diagnostic technologies, molecular mechanisms, therapeutic strategies and unresolved controversies.

Central to the review is the changing treatment context for lung cancer, particularly the advances in targeted therapy for epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma. By integrating clinical findings and molecular evidence, the review explores how transformation between these histologies has become an increasingly important focus of clinical and research attention. The diagnostic section addresses clinical manifestations associated with SCLC transformation and the technologies available to identify it.

The authors also consider the histologic and molecular features of the transformation process, bringing together evidence about how an NSCLC can acquire SCLC characteristics. The supplied abstract does not specify the exact diagnostic techniques, frequency of transformation or underlying molecular pathways; those details are not presented as findings here. Therapeutic approaches form another major part of the review.

The authors analyze treatment strategies in the setting of expanding options for NSCLC, including targeted therapy for EGFR-mutant lung adenocarcinoma, while considering ongoing controversies within the literature. The article is not presented as evidence that a particular treatment improves survival or establishes a new standard of care. Instead, it places current approaches in the broader context of NSCLC-to-SCLC transformation and identifies questions that remain under investigation.

Its stated purpose is to offer clinicians and researchers a reference that connects clinical manifestations, molecular mechanisms, diagnostic approaches and treatment modalities. It also points toward future perspectives, described in the abstract as areas for further investigation. Because the accessible source describes a literature synthesis without reporting a new cohort, experiment or comparative clinical trial, the article should be read as a structured overview of existing knowledge, associated controversies and unresolved questions rather than as new outcome data.

Subject of Research: Review of clinical, molecular, diagnostic and therapeutic evidence on NSCLC-to-SCLC transformation.

Article Title: Histologic and molecular transformation from non–small cell to small cell lung cancer: insights in the era of expanding treatment options

Article References: Wang, Z., Cai, G., Zhu, J., & Wang, J. (2026). Histologic and molecular transformation from non–small cell to small cell lung cancer: insights in the era of expanding treatment options. Medical Oncology, 43(11), Article 338. https://doi.org/10.1007/s12032-026-03451-y

Image Credits: AI Generated

DOI: 10.1007/s12032-026-03451-y

Keywords: NSCLC, SCLC, lung cancer, histologic transformation, molecular oncology, EGFR, lung adenocarcinoma, targeted therapy, cancer diagnostics, treatment strategies, Histologic, molecular